Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | PRKX | P51817 | 1/20 | 0.50 |
| ▸ | NEK2 | P51955 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31027884 | 1.00 | HDAC6 (0.64) | HDAC6DGAT1KCNH2TRPV1NPBWR1 | |
| SCHEMBL24141283 | 0.86 | DGAT1 (0.49) | HDAC6DGAT1KCNH2TRPV1NPBWR1 | |
| SCHEMBL5579984 | 0.86 | CHEK1 (0.59) | DGAT1KCNH2NPBWR1CHEK1PRKD3 | |
| SCHEMBL24141162 | 0.85 | DGAT1 (0.48) | HDAC6DGAT1KCNH2NPBWR1CHEK1 | |
| SCHEMBL21705321 | 0.84 | HDAC6 (0.66) | HDAC6TRPV1NPBWR1SCDTNKS | |
| SCHEMBL31027896 | 0.84 | HDAC6 (0.66) | HDAC6TRPV1NPBWR1SCDTNKS | |
| SCHEMBL21705325 | 0.82 | HDAC6 (0.64) | HDAC6DGAT1KCNH2TRPV1NPBWR1 | |
| SCHEMBL22452314 | 0.82 | HDAC6 (0.64) | HDAC6TRPV1NPBWR1RPS6KA3SCD | |
| SCHEMBL21705381 | 0.82 | HDAC6 (0.64) | HDAC6TRPV1NPBWR1SCDTNKS | |
| SCHEMBL22452444 | 0.82 | HDAC6 (0.64) | HDAC6TRPV1NPBWR1CLK4SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024137505-A2 | METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024105635-A1 | USES OF ZLN-005 AND RELATED COMPOUNDS | KYOTO PREFECTURAL UNIVERSITY OF MEDICINE (JP) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023244685-A1 | TREATMENT OF AGING-RELATED CHANGES AND DISEASES | TRANQUIS THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023205401-A1 | TREATMENT OF DISEASES ASSOCIATED WITH REDUCTIVE STRESS | Rdiscovery, LLC (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023081656-A1 | SELECTION AND TREATMENT OF SUBJECTS HAVING A CIRCULATING MYELOID CELL INFLAMMATORY PHENOTYPE | TRANQUIS THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2021262617-A1 | TREATMENT OF SYSTEMIC IMMUNE ACTIVATION SYNDROMES | TRANQUIS THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020033359-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 101/4885DGAT1 497/4885KCNH2 4528/4885 |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 91/4885DGAT1 800/4885KCNH2 4036/4885 |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 107/4885DGAT1 386/4885KCNH2 4569/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 107/4885DGAT1 386/4885KCNH2 4569/4885 |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 101/4885DGAT1 497/4885KCNH2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.